Another example of a new therapeutic target, whose degradation induced by PROTACs has been studied in leukemic cells is SHP2, which is a nonreceptor tyrosine phosphatase involved in some cancer cell signaling transductions, being associated with 4% cases of AML and in 7% cases of B‐cell ALL.180. Here, PTPN11 is linked to acute myeloid leukemia.